Alector, Inc.

ALEC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-142.9M $-119.0M $-130.4M $-133.3M $-36.3M $-190.2M $-105.4M $-52.2M
Depreciation & Amortization $5.7M $5.4M $5.7M $5.7M $6.3M $5.9M $3.8M $1.0M
Depreciation
Amortization
Stock-Based Compensation $26.7M $39.5M $42.8M $46.1M $40.8M $30.5M $16.3M $6.9M
Net Cash from Operating Activities $-184.0M $-229.9M $-184.2M $-20.3M $298.6M $-166.7M $-99.3M $127.5M
Investing Activities
Capital Expenditures $41.0K $1.3M $2.4M $4.1M $3.2M $5.0M $15.3M $1.9M
Business Acquisitions
Net Cash from Investing Activities $196.6M $107.1M $101.9M $-159.0M $-49.7M $-105.1M $-48.9M $-224.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $20.2M $81.5M $2.6M $4.5M $30.3M $232.1M $172.4M $131.1M
Net Change in Cash $32.8M $-41.2M $-79.7M $-174.8M $279.2M $-39.7M $24.2M $34.5M
Free Cash Flow $-184.1M $-231.2M $-186.5M $-24.4M $295.3M $-171.8M $-114.6M $125.6M
← Newer Page 1 of 2 Older →